Skip to main content

Avecho Biotechnology Health Care

$0.005 (0%)

High

$0.01

Low

$0.01

Trades

3

Turnover

$2,010

Volume

402,075
30 June 2023 at 11:45am
Register to track AVE and receive email alerts.
AVE Announcements on Price Chart

Latest Announcements

Headline Date
Update - Application for quotation of securities - AVE 28 June 2023 at 12:15pm
Application for quotation of securities - AVE 28 June 2023 at 12:10pm
AVE CBD capsule passes two-year stability milestone 22 June 2023 at 9:20am
AVE adds TPM cannabinoid gummies to portfolio 7 June 2023 at 9:45am
USPTO allows new TPM manufacturing patent 29 May 2023 at 9:40am
2023 Annual General Meeting Results 23 May 2023 at 3:40pm
Chair's Address and CEO Presentation 23 May 2023 at 1:15pm
Avecho licenses TPM for use in cancer drugs 22 May 2023 at 10:05am
Withdrawal of AGM Resolutions 5(c) and 5(d) 18 May 2023 at 9:15am
AVE commences manufacturing for Phase III trial 17 May 2023 at 9:45am
Change in Substantial Holding 16 May 2023 at 9:10am
Change of Director's Interest Notice x2 10 May 2023 at 9:40am
Top 20 Option Holders 10 May 2023 at 9:30am
Application for quotation of securities - AVE 10 May 2023 at 9:30am
Results of Entitlement Offer 9 May 2023 at 9:05am
Receipt of R&D Tax Incentive 2 May 2023 at 1:00pm
March 2023 Quarterly Activities Report & Appendix 4C 28 April 2023 at 9:50am
Notice of Annual General Meeting/Proxy Form 21 April 2023 at 9:05am
Notice to Ineligible Foreign Shareholders 13 April 2023 at 9:00am
Notice to Eligible Shareholders 13 April 2023 at 9:00am
Letter to Optionholders 3 April 2023 at 10:55am
Target Market Determination 3 April 2023 at 10:55am
Proposed issue of securities - AVE 3 April 2023 at 10:55am
Investor Presentation 3 April 2023 at 10:50am
Prospectus 3 April 2023 at 10:10am
Entitlement Offer to raise $11m for Phase 3 clinical trial 3 April 2023 at 10:05am
Avecho to present at NWR Virtual Healthcare Conference 17 March 2023 at 10:00am
Appendix 4G and Corporate Governance Statement 15 March 2023 at 5:55pm
Annual Report - 31 December 2022 15 March 2023 at 5:55pm
Appendix 4E - Preliminary Final Report 28 February 2023 at 9:40am
Clinical CBD program expands with the Lambert Initiative 22 February 2023 at 8:50am
December 2022 Quarterly Activities Report & Appendix 4C 31 January 2023 at 9:00am
Athenex submits Avecho's phytonadione to FDA pre-IND 12 January 2023 at 12:10pm
Avecho receives ethics approval for Phase III CBD trial 22 December 2022 at 10:20am
AVE signs development agreement with Perrigo 20 December 2022 at 9:20am
September 2022 Quarterly Activities Report & Appendix 4C 28 October 2022 at 9:00am
Increased CBD absorption in dogs vs commercial comparator 19 September 2022 at 10:25am
Application for quotation of securities - AVE 1 September 2022 at 9:40am
Section 708A Cleansing Statement 1 September 2022 at 9:25am
Appendix 4D and Half-year Financial Report 29 August 2022 at 9:35am
June 2022 Quarterly Activities Report & Appendix 4C 29 July 2022 at 8:59am
Security Class Reinstatement to Quotation- AVEO 14 July 2022 at 5:10pm
Update on Listed Options and Federal Court Application 14 July 2022 at 5:10pm
Suspension from Official Quotation - AVEO 8 June 2022 at 10:05am
Adoption of New Constitution 30 May 2022 at 4:40pm
2022 Annual General Meeting Results 30 May 2022 at 4:40pm
Chair's Address and CEO Presentation 30 May 2022 at 12:55pm
Receipt of R&D Tax Incentive 3 May 2022 at 12:55pm
March 2022 Quarterly Activities Report & Appendix 4C 29 April 2022 at 9:05am
Notice of Annual General Meeting/Proxy Form 28 April 2022 at 5:50pm
Register to track AVE and receive email alerts.